{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T22:13:10Z","timestamp":1787004790104,"version":"build-2736575974"},"reference-count":49,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T00:00:00Z","timestamp":1605571200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002997","name":"Nierstichting","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002997","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1053\/j.ajkd.2020.10.006","type":"journal-article","created":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T03:09:56Z","timestamp":1606187396000},"page":"719-729.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Comparative Effectiveness of Renin-Angiotensin System Inhibitors and Calcium Channel Blockers in Individuals With Advanced CKD: A Nationwide Observational Cohort Study"],"prefix":"10.1053","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9698-6825","authenticated-orcid":false,"given":"Edouard L.","family":"Fu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine M.","family":"Clase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bengt","family":"Lindholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joris I.","family":"Rotmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedo W.","family":"Dekker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merel","family":"van Diepen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4763-2024","authenticated-orcid":false,"given":"Juan-Jesus","family":"Carrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9069","key":"10.1053\/j.ajkd.2020.10.006_bib1","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/S0140-6736(96)11445-8","article-title":"Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia)","volume":"349","year":"1997","journal-title":"Lancet"},{"issue":"12","key":"10.1053\/j.ajkd.2020.10.006_bib2","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1053\/j.ajkd.2020.10.006_bib3","doi-asserted-by":"crossref","first-page":"73","DOI":"10.7326\/0003-4819-135-2-200107170-00007","article-title":"Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data","volume":"135","author":"Jafar","year":"2001","journal-title":"Ann Intern Med"},{"issue":"12","key":"10.1053\/j.ajkd.2020.10.006_bib4","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"9136","key":"10.1053\/j.ajkd.2020.10.006_bib5","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/S0140-6736(98)04433-X","article-title":"Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy","volume":"352","author":"Ruggenenti","year":"1998","journal-title":"Lancet"},{"issue":"6","key":"10.1053\/j.ajkd.2020.10.006_bib6","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1681\/ASN.2006101081","article-title":"Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease","volume":"18","author":"Kent","year":"2007","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2020.10.006_bib7","first-page":"337","article-title":"KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"issue":"19","key":"10.1053\/j.ajkd.2020.10.006_bib8","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/j.jacc.2017.11.006","volume":"71","author":"Whelton","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"33","key":"10.1053\/j.ajkd.2020.10.006_bib9","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"issue":"12","key":"10.1053\/j.ajkd.2020.10.006_bib10","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1681\/ASN.V12122832","article-title":"Gruppo Italiano di Studi Epidemiologici in N. ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy","volume":"12","author":"Ruggenenti","year":"2001","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"19","key":"10.1053\/j.ajkd.2020.10.006_bib11","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","article-title":"Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial","volume":"288","author":"Wright","year":"2002","journal-title":"JAMA"},{"key":"10.1053\/j.ajkd.2020.10.006_bib12","doi-asserted-by":"crossref","first-page":"f6008","DOI":"10.1136\/bmj.f6008","article-title":"Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis","volume":"347","author":"Wu","year":"2013","journal-title":"BMJ"},{"issue":"5","key":"10.1053\/j.ajkd.2020.10.006_bib13","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1053\/j.ajkd.2015.10.011","article-title":"Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials","volume":"67","author":"Xie","year":"2016","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1053\/j.ajkd.2020.10.006_bib14","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1053\/j.ajkd.2018.06.010","article-title":"Use of renin-angiotensin system blockade in advanced CKD: an NKF-KDOQI Controversies Report","volume":"72","author":"Weir","year":"2018","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1053\/j.ajkd.2020.10.006_bib15","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.kint.2018.02.006","article-title":"Improving the prognosis of patients with severely decreased glomerular filtration rate (CKD G4+): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"93","author":"Eckardt","year":"2018","journal-title":"Kidney Int"},{"issue":"2","key":"10.1053\/j.ajkd.2020.10.006_bib16","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1056\/NEJMoa053107","article-title":"Efficacy and safety of benazepril for advanced chronic renal insufficiency","volume":"354","author":"Hou","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1053\/j.ajkd.2020.10.006_bib17","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1001\/jamainternmed.2013.12700","article-title":"Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia","volume":"174","author":"Hsu","year":"2014","journal-title":"JAMA Intern Med"},{"issue":"10","key":"10.1053\/j.ajkd.2020.10.006_bib18","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.jash.2017.07.006","article-title":"Effect of dual compared to no or single renin-angiotensin system blockade on risk of renal replacement therapy or death in predialysis patients: PREPARE-2 study","volume":"11","author":"Voskamp","year":"2017","journal-title":"J\u00a0Am Soc Hypertens"},{"issue":"1","key":"10.1053\/j.ajkd.2020.10.006_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0170874","article-title":"The impact of renin-angiotensin system blockade on renal outcomes and mortality in pre-dialysis patients with advanced chronic kidney disease","volume":"12","author":"Oh","year":"2017","journal-title":"PLoS One"},{"issue":"5","key":"10.1053\/j.ajkd.2020.10.006_bib20","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/sj.ki.5000159","article-title":"ACE-inhibitor use and the long-term risk of renal failure in diabetes","volume":"69","author":"Suissa","year":"2006","journal-title":"Kidney Int"},{"issue":"9","key":"10.1053\/j.ajkd.2020.10.006_bib21","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.2215\/CJN.03060319","article-title":"Association of acute increases in plasma creatinine after renin-angiotensin blockade with subsequent outcomes","volume":"14","author":"Fu","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"issue":"11","key":"10.1053\/j.ajkd.2020.10.006_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0078465","article-title":"ACE inhibitor and angiotensin receptor-II antagonist prescribing and hospital admissions with acute kidney injury: a longitudinal ecological study","volume":"8","author":"Tomlinson","year":"2013","journal-title":"PLoS One"},{"issue":"3","key":"10.1053\/j.ajkd.2020.10.006_bib23","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.xkme.2019.12.007","article-title":"ACE inhibitor\/angiotensin receptor blocker use patterns in advanced CKD and risk of kidney failure and death","volume":"2","author":"Arora","year":"2020","journal-title":"Kidney Med"},{"issue":"19","key":"10.1053\/j.ajkd.2020.10.006_bib24","article-title":"Use of antihypertensive agents and association with risk of adverse outcomes in chronic kidney disease: focus on angiotensin-converting enzyme inhibitors and angiotensin receptor blockers","volume":"7","author":"Ku","year":"2018","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"7","key":"10.1053\/j.ajkd.2020.10.006_bib25","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1111\/jch.13563","article-title":"Prescription of renin-angiotensin-aldosterone system inhibitors (RAASi) and its determinants in patients with advanced CKD under nephrologist care","volume":"21","author":"Pecoits-Filho","year":"2019","journal-title":"J\u00a0Clin Hypertens (Greenwich)"},{"issue":"4","key":"10.1053\/j.ajkd.2020.10.006_bib26","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s40265-019-1064-1","article-title":"Management of hypertension in chronic kidney disease","volume":"79","author":"Pugh","year":"2019","journal-title":"Drugs"},{"issue":"1","key":"10.1053\/j.ajkd.2020.10.006_bib27","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1053\/j.ajkd.2018.12.044","article-title":"Hypertension in CKD: Core Curriculum 2019","volume":"74","author":"Ku","year":"2019","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"10.1053\/j.ajkd.2020.10.006_bib28","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2215\/CJN.04330418","article-title":"Clinical pharmacology of antihypertensive therapy for the treatment of hypertension in CKD","volume":"14","author":"Sinha","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2020.10.006_bib29","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1093\/ndt\/gfv298","article-title":"Trends in haemoglobin, erythropoietin-stimulating agents and iron use in Swedish chronic kidney disease patients between 2008 and 2013","volume":"31","author":"Evans","year":"2016","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"10.1053\/j.ajkd.2020.10.006_bib30","first-page":"1892","article-title":"Initiation of erythropoiesis-stimulating agents and outcomes: a nationwide observational cohort study in anaemic chronic kidney disease patients","volume":"32","author":"Evans","year":"2017","journal-title":"Nephrol Dial Transplant"},{"issue":"7","key":"10.1053\/j.ajkd.2020.10.006_bib32","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/pds.1294","article-title":"The new Swedish Prescribed Drug Register--opportunities for pharmacoepidemiological research and experience from the first six months","volume":"16","author":"Wettermark","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1053\/j.ajkd.2020.10.006_bib33","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1186\/1471-2458-11-450","article-title":"External review and validation of the Swedish national inpatient register","volume":"11","author":"Ludvigsson","year":"2011","journal-title":"BMC Public Health"},{"issue":"9","key":"10.1053\/j.ajkd.2020.10.006_bib34","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s10654-017-0316-1","article-title":"The Swedish cause of death register","volume":"32","author":"Brooke","year":"2017","journal-title":"Eur J Epidemiol"},{"issue":"4","key":"10.1053\/j.ajkd.2020.10.006_bib35","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/aje\/kwr301","article-title":"Bias in observational studies of prevalent users: lessons for comparative effectiveness research from a meta-analysis of statins","volume":"175","author":"Danaei","year":"2012","journal-title":"Am J Epidemiol"},{"issue":"10","key":"10.1053\/j.ajkd.2020.10.006_bib36","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1093\/ndt\/gfy283","article-title":"Merits and caveats of propensity scores to adjust for confounding","volume":"34","author":"Fu","year":"2019","journal-title":"Nephrol Dial Transplant"},{"issue":"12","key":"10.1053\/j.ajkd.2020.10.006_bib37","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1002\/sim.4780091214","article-title":"Relation of pooled logistic regression to time dependent Cox regression analysis: the Framingham Heart Study","volume":"9","author":"D\u2019Agostino","year":"1990","journal-title":"Stat Med"},{"key":"10.1053\/j.ajkd.2020.10.006_bib38","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jclinepi.2017.11.021","article-title":"Electronic medical records can be used to emulate target trials of sustained treatment strategies","volume":"96","author":"Danaei","year":"2018","journal-title":"J\u00a0Clin Epidemiol"},{"issue":"11","key":"10.1053\/j.ajkd.2020.10.006_bib39","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1093\/ndt\/gft355","article-title":"When do we need competing risks methods for survival analysis in nephrology?","volume":"28","author":"Noordzij","year":"2013","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1053\/j.ajkd.2020.10.006_bib40","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/aje\/kwp107","article-title":"Competing risk regression models for epidemiologic data","volume":"170","author":"Lau","year":"2009","journal-title":"Am J Epidemiol"},{"issue":"6","key":"10.1053\/j.ajkd.2020.10.006_bib41","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1161\/CIRCULATIONAHA.115.017719","article-title":"Introduction to the analysis of survival data in the presence of competing risks","volume":"133","author":"Austin","year":"2016","journal-title":"Circulation"},{"issue":"4","key":"10.1053\/j.ajkd.2020.10.006_bib42","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1080\/10543406.2020.1730868","article-title":"Comparison of propensity score methods for pre-specified subgroup analysis with survival data","volume":"30","author":"Izem","year":"2020","journal-title":"J\u00a0Biopharm Stat"},{"key":"10.1053\/j.ajkd.2020.10.006_bib43","doi-asserted-by":"crossref","first-page":"b2393","DOI":"10.1136\/bmj.b2393","article-title":"Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls","volume":"338","author":"Sterne","year":"2009","journal-title":"BMJ"},{"issue":"26","key":"10.1053\/j.ajkd.2020.10.006_bib44","doi-asserted-by":"crossref","first-page":"5120","DOI":"10.1002\/sim.8355","article-title":"Avoiding pitfalls when combining multiple imputation and propensity scores","volume":"38","author":"Granger","year":"2019","journal-title":"Stat Med"},{"issue":"9502","key":"10.1053\/j.ajkd.2020.10.006_bib45","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1016\/S0140-6736(05)67814-2","article-title":"Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis","volume":"366","author":"Casas","year":"2005","journal-title":"Lancet"},{"issue":"9","key":"10.1053\/j.ajkd.2020.10.006_bib46","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1093\/ndt\/gfq792","article-title":"Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials","volume":"26","author":"Maione","year":"2011","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"10.1053\/j.ajkd.2020.10.006_bib47","doi-asserted-by":"crossref","first-page":"570","DOI":"10.7326\/0003-4819-156-8-201204170-00008","article-title":"Screening for, monitoring, and treatment of chronic kidney disease stages 1 to 3: a systematic review for the U.S. Preventive Services Task Force and for an American College of Physicians clinical practice guideline","volume":"156","author":"Fink","year":"2012","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1053\/j.ajkd.2020.10.006_bib48","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-009147","article-title":"Calcium channel blockers and cancer: a risk analysis using the UK Clinical Practice Research Datalink (CPRD)","volume":"6","author":"Grimaldi-Bensouda","year":"2016","journal-title":"BMJ Open"},{"key":"10.1053\/j.ajkd.2020.10.006_bib49","first-page":"1","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","year":"2013","journal-title":"Kidney Int Suppl"},{"key":"10.1053\/j.ajkd.2020.10.006_bib50","doi-asserted-by":"crossref","first-page":"f5680","DOI":"10.1136\/bmj.f5680","article-title":"Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials","volume":"347","author":"Ninomiya","year":"2013","journal-title":"BMJ"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638620311215?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638620311215?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T03:32:49Z","timestamp":1759462369000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638620311215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S0272638620311215"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2020.10.006","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative Effectiveness of Renin-Angiotensin System Inhibitors and Calcium Channel Blockers in Individuals With Advanced CKD: A Nationwide Observational Cohort Study","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2020.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}